J. Goldman & Co LP acquired a new position in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 198,732 shares of the company's stock, valued at approximately $2,049,000. J. Goldman & Co LP owned about 0.28% of Immix Biopharma as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Allworth Financial LP purchased a new position in Immix Biopharma during the 4th quarter worth approximately $30,000. Legal & General Group Plc acquired a new stake in shares of Immix Biopharma in the second quarter worth $41,000. Mathes Company Inc. purchased a new position in shares of Immix Biopharma during the fourth quarter worth $56,000. Compass Financial Management LLC purchased a new position in shares of Immix Biopharma during the second quarter worth $56,000. Finally, Balyasny Asset Management L.P. acquired a new position in Immix Biopharma during the fourth quarter valued at $67,000. Institutional investors and hedge funds own 11.26% of the company's stock.
Immix Biopharma Trading Up 6.3%
Shares of IMMX stock opened at $14.47 on Wednesday. Immix Biopharma, Inc. has a 12-month low of $1.94 and a 12-month high of $15.10. The business's 50 day moving average is $10.30 and its two-hundred day moving average is $9.40. The company has a market capitalization of $1.04 billion, a P/E ratio of -16.44 and a beta of 0.11.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its earnings results on Friday, August 7th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). On average, research analysts predict that Immix Biopharma, Inc. will post -0.74 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts have weighed in on IMMX shares. Lifesci Capital assumed coverage on Immix Biopharma in a research report on Wednesday, June 17th. They set an "outperform" rating and a $19.00 price target on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Immix Biopharma in a research note on Friday, July 17th. Citigroup reiterated a "market outperform" rating on shares of Immix Biopharma in a research report on Friday, August 14th. Morgan Stanley dropped their price objective on shares of Immix Biopharma from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 11th. Finally, Needham & Company LLC started coverage on shares of Immix Biopharma in a research note on Wednesday, July 22nd. They issued a "buy" rating and a $21.00 target price for the company. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $21.29.
Check Out Our Latest Stock Analysis on Immix Biopharma
About Immix Biopharma
(
Free Report)
Immix Biopharma NASDAQ: IMMX is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company's approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.
The company's lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
